Studie ACE-536-MDS-001

ACE-536-MDS-001

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects with Ring Sideroblasts Who Require Red Blood Cell Transfusions,

NCT02631070

3. Med 3. Med Ismaninger Str. 22 81675 München Germany

III

Rekrutierung beendet

Positiv

2016-04-07

Unbekannt / Unbekannt

Chemo